Pentoxifylline and Progression of Chronic Kidney Disease in Moderate-to-high Risk Patients
Status:
Completed
Trial end date:
2008-04-01
Target enrollment:
Participant gender:
Summary
The purpose of the investigators study is to assess the impact of therapy with Pentoxifylline
(PTF), a nonspecific phosphodiesterase inhibitor, on kidney function in patients at high-risk
for progression to end-stage renal disease. The investigators hypothesize that therapy with
Pentoxifylline will slow progression of kidney disease over time.